Cholesterol is not your enemy: when insulin falls, the liver produces cholesterol not because it is harmful but because it is the raw material for vitamin D, sex hormones, cortisol and bile salts.
Original statement
الكوليسترول ليس عدوّك — بل هو مصنع هرموناتك
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Cholesterol is not your enemy: when insulin falls, the liver produces cholesterol not because it is harmful but because it is the raw material for vitamin D, sex hormones, cortisol and bile salts.
Origin
- Source status
- Third-party site (unofficial)
- Attribution
- Third-party site altayybat.com (unofficial)
- Origin
- https://altayybat.com/ar/
- Attribution uncertainty
- Unofficial fan/summary site; lowest attribution level; no video references given. Summary of Elawady's view on cholesterol.
- Claimed mechanism
Hepatic cholesterol synthesis supplies steroid hormones, vitamin D and bile acids; high insulin impairs this.
- Claimed health effect
Cholesterol is beneficial; insufficiency leads to vitamin D deficiency and hormonal weakness.
- Population concerned
Everyone.
- Geographic restriction by Elawady
none found
Diverging source versions
كل ده عشان انت خدت كل الكوليسترول اللي بتصنعه من الكبد عملت بيه كوليسترول كورتيزون
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! الكورتيزون حياتك (Open source)
- Published
- 17 October 2025
- Timestamp
- 1:42:28 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain transcription errors; spoken live-stream language, context partly conversational.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Cholesterol is beneficial, not harmful.
2. What is demonstrably correct?
Cholesterol is an essential molecule: it is the precursor of steroid hormones (cortisol, sex hormones), vitamin D and bile acids, and a component of cell membranes (textbook physiology).
3. What is wrong or exaggerated?
Being essential does not mean that high levels in blood are harmless. Elevated LDL cholesterol causes atherosclerotic cardiovascular disease (I-FAT-02); lowering it reduces events. The body can produce sufficient cholesterol for hormones even when LDL is lowered by diet or drugs (general clinical knowledge).
4. What remains unclear?
The specific claim that high insulin impairs hepatic cholesterol synthesis and causes vitamin D deficiency was not examined and appears to lack evidence (not searched in depth).
5. Which studies support it?
None for the implied harmlessness. The best available support is a systematic review showing that LDL cholesterol is not positively associated with mortality in people over 60 (I-FAT-109), which is weakened by reverse causation (illness lowers cholesterol).
6. Which studies contradict it?
I-FAT-02; I-FAT-110 (CTT 2019: LDL lowering reduces major vascular events at all ages without increasing non-vascular death or cancer); I-INTB-18 (CTT 2010).
7. What applies to Germany and Europe?
Universal.
8. What is known about Egypt?
Universal.
9. What practical conclusion is appropriate?
Cholesterol is necessary, but high LDL cholesterol is a risk factor that should be taken seriously.
Assessment details
- Rationale for certainty of evidence
The biochemical role of cholesterol is textbook knowledge, but the implied message that blood cholesterol is not harmful contradicts strong evidence that LDL cholesterol causes atherosclerosis.
- Source quality
Third-party summary; consistent with Elawady's statements in transcripts.
- Regional transferability
Universal.
- Individual exceptions
Very low cholesterol states are rare and usually disease-related.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: Is cholesterol harmless because it is the precursor of vitamin D, steroid hormones and bile acids, so that elevated blood cholesterol is not a concern?
Research question in detail (PECO)
- Population
- Adults with elevated LDL
- Intervention or exposure
- Elevated LDL cholesterol
- Comparison
- Lower LDL
- Geographic scope
- universal physiology
- Outcomes
- Atherosclerotic cardiovascular events
- Mortality
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
In older people, higher LDL was not linked to earlier death in cohort studies
Ravnskov U et al.. BMJ Open 2016 · PMID 27292972 · DOI 10.1136/bmjopen-2015-010401 Systematic reviewabstract checkednewly addedSystematic review: in people over 60, LDL-C was not positively, and often inversely, associated with mortality.
- Actual result
- Inverse association in 16 of 28 cohorts.
- Methodological quality
- low (vote counting, reverse causation)
- Relevance
- indirect
- Limitations
- Frailty and illness lower cholesterol; contradicted by RCTs.
What speaks against the claim?
Lowering LDL cholesterol prevents heart attacks and strokes at all ages
Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1 Meta-analysisabstract checkednewly addedCTT IPD meta-analysis: lowering LDL reduces major vascular events at all ages, without increasing non-vascular death or cancer.
- Actual result
- RR 0.79 (0.77-0.81) per 1.0 mmol/L.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Drug-induced LDL lowering.
Experts: LDL cholesterol causes artery disease
Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144 Guideline / position statementfull text, structured risk-of-bias assessmentEAS consensus: LDL causes ASCVD.
- Actual result
- As registered.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- None.
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5 Meta-analysisfull text, structured risk-of-bias assessmentCTT 2010: LDL lowering reduces events and all-cause mortality.
- Actual result
- Mortality RR 0.90 (0.87-0.93) per 1.0 mmol/L.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Drug trials.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Cholesterol is essential, but elevated LDL cholesterol is a proven cause of atherosclerosis, and lowering it reduces events without impairing non-vascular outcomes.
Why some studies weigh more
Randomised and genetic evidence outweighs observational associations in the elderly that are confounded by frailty.
Is a causal relationship established? Yes, established LDL causality established.
Remaining uncertainty
The specific claim about insulin and hepatic cholesterol production was not examined in depth.
Justified conclusion
The biological role is described correctly; the implied conclusion that high blood cholesterol is harmless is wrong.
Why do studies seem to disagree?
Observational inverse associations in old age (I-FAT-109) reflect reverse causation; randomised trials in the same age groups (I-FAT-110) show benefit of LDL lowering.
Does this depend on the country?
- General biological effects
- Universal.
A regional difference that changes the conclusion is not supported by robust data.
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- ASCVD events per LDL reduction
- Starting level
- high (randomised trials)
- Reasons for upgrading
- dose-response
- consistency
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ESC/EAS: 2019 ESC/EAS Guidelines for the management of dyslipidaemias (PMID 31504418) and 2025 Focused Update (PMID 40878289) (2019/2025) · Original publication could not be retrieved; content not used
- WHO: Saturated fatty acid and trans-fatty acid intake for adults and children: WHO guideline (2023) · Original publication
Landing page fetched (17 July 2023). Recommendations as registered in I-FAT-08: reduce saturated fat to 10% of energy (strong); replace with PUFA (strong), plant MUFA or fibre-rich carbohydrate (conditional).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | ("LDL cholesterol"[tiab] OR LDL-C[tiab]) AND (elderly[tiab] OR older[tiab]) AND mortality[tiab] AND (inverse*[tiab]) AND systematic review[pt] | supporting evidence | 1 | |
| Europe PMC | 26 October 2026 | "LDL" AND mortality AND (elderly OR "older people") AND ("inverse association" OR "reverse causation") | supporting evidence | 2853 | |
| Europe PMC | 26 October 2026 | ("cholesterol hypothesis" OR "LDL hypothesis" OR "diet-heart hypothesis") AND (critique OR questioned OR inconsistent OR "does not cause") | supporting evidence | 115 | |
| Europe PMC | 26 October 2026 | ("very low LDL" OR "extremely low LDL") AND (steroid OR cortisol OR testosterone OR "adrenal" OR "vitamin D") AND (PCSK9 OR evolocumab OR alirocumab) | both directions | 95 | |
| PubMed | 26 October 2026 | Cholesterol Treatment Trialists[cn] AND older[ti] | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | TITLE:"Efficacy and safety of statin therapy in older people" | contradicting evidence | 1 |
Open questions
Mechanistic claim about insulin and hepatic cholesterol synthesis.
How deeply was this checked?
4 linked studies: 2 checked in full text (2 of them with a structured risk-of-bias assessment), 2 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly false (moderate)
The best supporting evidence (I-FAT-109) is weak and contradicted by randomised evidence in the same age group (I-FAT-110). The verdict stays “Mostly false” because the biochemical part is correct; certainty kept at moderate for the bundled statement.
New sources: I-FAT-109 I-FAT-110
In plain language
It is true that the body needs cholesterol to make hormones, vitamin D and bile. But too much LDL cholesterol in the blood damages arteries over time; this has been shown by many types of research. Saying 'cholesterol is not your enemy' can mislead people with high cholesterol into ignoring it.
Studies on this claim
Studies supporting the claim (1)
-
In older people, higher LDL was not linked to earlier death in cohort studies
Ravnskov U et al.. BMJ Open 2016 · PMID 27292972 · DOI 10.1136/bmjopen-2015-010401Systematic reviewindependent cross-checkabstract checkedInverse association in 16 of 28 cohorts.
LDL-C not positively associated with mortality in elderly cohorts (high risk of bias).
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Check LDL and death in the elderly.
- How was the study done?
Systematic review, vote counting.
- How many people, animals or samples were studied?
68,094 people.
- What was actually found?
Higher LDL not linked to more deaths.
- How large was the observed effect?
No pooled estimate.
- What do the results mean in everyday life?
Low cholesterol in old age often reflects illness.
- What are the study's limitations?
Reverse causation; weak methods.
- What does it say about Elawady's specific claim?
Weak support for the claim.
- Do the results apply to Germany and Europe?
n/a
- What can explicitly not be concluded from this study?
Cannot show LDL is harmless.
No study in this group is marked as key.
Studies contradicting or limiting the claim (3)
-
Experts: LDL cholesterol causes artery disease
Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144Guideline / position statementindependent cross-checkfull text, structured risk-of-bias assessment★ key studyGenetic studies, cohorts and drug trials agree: more LDL over time means more atherosclerosis.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Establish whether LDL is causal.
- How was the study done?
Consensus review of all evidence types.
- How many people, animals or samples were studied?
>2 million people.
- What was actually found?
LDL causes ASCVD.
- How large was the observed effect?
Log-linear dose-response.
- What do the results mean in everyday life?
High LDL is harmful.
- What are the study's limitations?
Expert consensus, not a systematic review; most panel members have ties to cholesterol-drug makers; absolute-benefit tables are projections.
- What does it say about Elawady's specific claim?
Contradicts claims that fat/cholesterol cannot harm arteries.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effects of single foods.
-
Lowering LDL cholesterol prevents heart attacks and strokes at all ages
Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1Meta-analysisindependent cross-checkabstract checked★ key study21% fewer major vascular events per 1 mmol/L lower LDL, including older people.
LDL lowering reduces events at all ages.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test statins at different ages.
- How was the study done?
IPD meta-analysis of 28 RCTs.
- How many people, animals or samples were studied?
186,854 people.
- What was actually found?
Benefit at all ages.
- How large was the observed effect?
RR 0.79 per mmol/L.
- What do the results mean in everyday life?
High LDL matters even in older age.
- What are the study's limitations?
Drug trials.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
Universal.
- What can explicitly not be concluded from this study?
Cannot directly test dietary cholesterol.
-
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyEach 1 mmol/L LDL reduction cut major vascular events by about a fifth and deaths by 10%, without more cancer.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess statin efficacy and safety
- How was the study done?
IPD meta-analysis
- How many people, animals or samples were studied?
about 170,000
- What was actually found?
Fewer heart attacks, strokes and deaths
- How large was the observed effect?
RR 0.78 per mmol/L for major vascular events; 2.8% vs 3.6% events per year (statin vs control)
- What do the results mean in everyday life?
Statins prevent heart attacks and strokes; the absolute gain is larger the higher the person's risk.
- What are the study's limitations?
Most trials industry-funded; data from 3 trials unavailable; only severe muscle damage (rhabdomyolysis) assessed
- What does it say about Elawady's specific claim?
Contradicts 'statins are forbidden'.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not decide whether a specific low-risk person needs a statin.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Universal.
Egypt
Universal.
What applies in my country?
General scientific assessment
Mostly false Cholesterol is essential, but high LDL cholesterol is a proven cause of artery disease.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review.. Ravnskov U et al.. BMJ Open 2016 · PMID 27292972 · DOI 10.1136/bmjopen-2015-010401
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.. Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.. Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.. CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5